Cytotoxic and cytostatic effects of anti-Thy 1.2 targeted doxorubicin and cyclosporin A

Journal of Controlled Release

Volumn 40, Issue 3, 1996, Pages 303-319

  Rihova B ^a   Strohalm, J ^b   Plocova D ^b   Subr V ^b   Srogl J ^a   Jelinkova M ^a   Sirova M ^a   Ulbrich, K ^b  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Affinity therapy; Antibody targeting; Anticancer drugs; Cyclosporin A; Doxorubicin; Immunosuppression; N (2 hydroxypropyl)methacrylamide copolymers; Polymeric carrier; Targetable drugs

Indexed keywords

COPOLYMER; CYCLOSPORIN A; CYTOSTATIC AGENT; DOXORUBICIN; MONOCLONAL ANTIBODY;

AMINO ACID ANALYSIS; ANIMAL CELL; ARTICLE; CYTOFLUOROMETRY; CYTOTOXICITY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOMA;

EID: 0029893387     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(95)00198-0     Document Type: Article

References (37)

1. A. Maraveyas and A.A. Epenetos, Targeted immunotherapy. An update with special emphasis on ovarian cancer, Acta Oncol. 32 (1993) 741-746.
2. B. Říhová, R.C. Rathi, P. Kopečková and J. Kopeček, In vitro bioadhesion of carbohydrate-containing N-(2-hydroxypropyl)methacrylamide copolymers to the GI tract of guinea pigs, Int. J. Pharm. 87 (1992) 105-116.
3. R. Duncan, Drug-polymer conjugates: potential for improved chemotherapy, Anti-Cancer Drugs 3 (1992) 175-210.
4. L.W. Seymour, K.B. O'Harre, R. Duncan, J. Strohaim and K. Ulbrich, First- and second-order drug targeting to hepatic melanoma metastases. Br. J. Cancer 63 (1993) 833.
5. E.S. Vitetta, M. Stone, P. Amlot, J. Fay, R. May, M. Till, J. Newman, P. Clark, R. Collins, D. Cunningham, V. Gethie, J.W. Uhr and P.E. Thorpe, Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51 (1991) 4052-4061.
6. P.L. Tazzari, S. Zhang, Q. Chen, S. Sforzini, A. Bolognesi, F. Stirpe, H. Xie, A. Moretta and S. Ferrini, Targeting of saporin to CD25-positive normal and neoplastic lymphocyte by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation, Br. J. Cancer 67 (1993) 1248-1253.
7. G. Paganelli, P. Magnani and F. Zito, Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 51 (1991) 5960-5966.
8. H.J. Haisma, E. Boven and M. van Muijen, Analysis of a conjugate between anticarcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate, Cancer Immunol. Immunother. 34 (1991) 343-352.
9. J. Kopeček, Targetable polymeric anticancer drugs: temporal control of drug activity, Ann. NY Acad. Sci. 618 (1991) 335-344.
10. P. Rejmanová, J. Kopeček, R. Duncan and J.B. Lloyd, Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)-methacrylamide copolymers, Biomaterials 6 (1985) 45-48.
11. B. Říhová, P. Kopečková, J. Strohalm, P. Rossmann, V. Větvička and J. Kopeček, Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugates to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46 (1988) 100-114.
12. R. Duncan, L.W. Seymour, K.B. O'Harre, P.A. Flanagan, S. Wedge, K. Ulbrich, J. Strohalm, V. Šubr, F. Spreafico, M. Grandi, M. Ripamonti, M. Faroa and A. Suarato, Preclinical evaluation of polymer-bound doxorubicin, J. Control. Rel. 19 (1992) 331-346.
13. B. Říhová, M. Bilej, V. Větvička, K. Ulbrich, J. Strohalm, J. Kopeček and R. Duncan, Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity. effect on haematopoietic stem cells in bone marrow in vivo and effect on mouse splenocytes and human peripheral blood lymphocytes in vitro, Biomaterials 10 (1989) 335-342.
14. T.K. Yeung, J.W. Hopewell, R.H. Simmonds, L.W. Seymour, R. Duncan, O. Bellini, M. Grandi, F. Spreafico, J. Strohalm and K. Ulbrich, Reduced cardiotoxicity of doxorubicin administered in the form of N-(2-hydroxypropyl)-methacrylamide copolymer conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol. 29 (1991) 105-111.
15. B. Říhová, A. Jegorov, J. Strohalm, V. Maťha, P. Rossmann, L. Fornůsek and K. Ulbrich. Antibody-targeted cyclosporin A. J. Control. Rel. 19 (1992) 25-40.
16. M. Šťestný, B. Říhová, J. Strohalm and K. Ulbrich, Compari-son of the binding kinetics of antibody-targeted HPLA-bound doxorubicin in vitro and in vivo, J. Control. Rel. (1996) in press.
17. A. Jegorov, Czech. Pat. Appl. PV 6498/89 and 6499/89, 1989.
18. A. Jegorov, B. Říhová, K. Ulbrich, V. Maťha, J. Strohalm and L. Fornůsek, Eur. Pat. 0536343/95, Czech Pat. 279785/1995.
19. P. Dráber, J. Zikán and M. Vojtíšková, Establishment and characterization of permanent murine hybridomas secreting monoclonal anti-Thy-1 antibodies, J. Immunogenet. 7 (1980) 455-474.
20. J. Kopeček, P. Rejmanová and V. Chytrý, Polymers containing enzymatically degradable bonds. 1. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide, Makromol. Chem. 182 (1981) 799-809.
21. P. Rejmanová, J. Pohl, M. Baudyš, V. Kostka and J. Kopeček, Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B, Makromol. Chem. 184 (1983) 2009-2020.
22. B. Říhová and J. Kopeček, Biological properties of targetable poly-[N-(2-hydroxypropyl)methacrylamide]-antibody conjugates, J. Control. Rel. 2 (1985) 289-310.
23. B. Říhová. J. Strohalm, D. Plocová and K. Ulbrich, Selectivity of antibody-targeted anthracycline antibiotics on T lymphocytes, J. Bioact. Comp. Polym. 5 (1990) 249-266.
24. V. Šubr, J. Strohalm, K. Ulbrich, R. Duncan and I.C. Hume, Polymers containing enzymatically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)methacrylamide] copolymer drug carriers in vitro and antitumor activity measured in vivo, J. Control. Rel. 18 (1992) 123-132.
25. M. Šírová, B. Říhová and I. Říha, IL-2 and IL-3 production in high and low IgG-responding strains of mice. Immunol. Lett. 37 (1993) 91-96.
26. N.L. Letvin, J. Ritz, L.J. Guida, J.M. Yetz, J.M. Lambert, E.L. Reinherz and S.F. Schlossman, In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. I. Effects of anti-T11 antibodies on the circulating T cell pool, Blood 66 (1985) 961-966.
27. O.W. Press, A.G. Farr, K.I. Borroz, S.K. Anderson and P.J. Martin, Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies, Cancer Res. 49 (1989) 4906-4912.
28. G.S. Tarnowski, P. Ralph and C.Ch. Stock, Sensitivity to chemotherapeutic and immunomodulating agents of two mouse lymphomas and of a macrophage tumor. Cancer Res. 39 (1979) 3964-3967.
29. M. Jelínková, J. Strohalm, K. Ulbrich, J. Šrogl, M. Šťastný and B. Říhová, In vivo effect of anti Thy 1.2 targeted doxorubicin on EL-4 mouse thymoma. To be published.
30. W. Priebe and R. Perez-Soler. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach, Pharmacol. Ther. 60 (1993) 215-234.
31. 3 subclass, J. Immunol. 138 (1987) 2979-2981.
32. a monoclonal antibodies and macrophages, in: R.A. Reisfeld and S. Sell (eds), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, New York, 1985, pp. 165-172.
33. S.H. Bridges, A.M. Kruisbeck and D.L. Longo, Selective in vivo antitumor effects of monoclonal anti I-A antibody on B cell lymphoma, J. Immunol. 139 (1987) 4242-4249.
34. S.E. Order, G.B. Stillwagon, J.L. Klein, P.K. Leichner, S.S. Siegelman, E.K. Fishman, D.S. Ettinger, T. Haulk, K. Kopher, K. Finney, M. Surdyke, S. Self and S. Leibel, Iodine-131 antiferritin, a new treatment modality in hepatoma: a radiation therapy oncology group study, J. Clin. Oncol. 3 (1985) 1573-1582.
35. A. Rao, NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes, Immunol. Today 15 (1994) 468-281.
36. T.F.G. Henn, M.C. Garnett, S.R. Chhabra, B.W. Bycroft and R.W. Baldwin, Synthesis of 2′-deoxyuridine and 5-fluoro-2′-deoxyuridine derivatives and evaluation in antibody targeting studies, J. Med. Chem. 36 (1993) 1570-1579.
37. W. Priebe and R. Perez-Soler, Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol. Ther. 60 (1993) 215-234.